Jeannine Bouzy

Viable Malignant Cells After Primary Chemotherapy for Disseminated Nonseminomatous Germ Cell Tumors: Prognostic Factors and Role of Postsurgery Chemotherapy—Results From an International Study Group

Karim Fizazi, Sergei Tjulandin, Roberto Salvioni et al. · Journal of Clinical Oncology · 2001 · 280 citations

Medicine, Oncology, Surgery +15

Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer

Karim Fizazi, Philippe Beuzeboc, J. Lumbroso et al. · Journal of Clinical Oncology · 2009 · 173 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study—Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)

Stéphane Culine, Alain Lortholary, Jean‐Jacques Voigt et al. · Journal of Clinical Oncology · 2003 · 153 citations

Medicine, Oncology, Pharmacology +12

Early Predicted Time to Normalization of Tumor Markers Predicts Outcome in Poor-Prognosis Nonseminomatous Germ Cell Tumors

Karim Fizazi, Stéphane Culine, Andrew Kramar et al. · Journal of Clinical Oncology · 2004 · 144 citations

Medicine, Oncology, Chemotherapy +15

Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP

Stéphane Culine, Andrew Kramar, Christine Théodore et al. · Journal of Clinical Oncology · 2008 · 102 citations · Full text

Medicine, Oncology, Pharmacology +13